Drug Profile
Research programme: non-retinoid visual cycle modulators - Kubota Vision
Latest Information Update: 07 Apr 2020
Price :
$50
*
At a glance
- Originator Acucela
- Developer Kubota Vision
- Class Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic retinopathy; Retinopathy of prematurity; Stargardt disease
Most Recent Events
- 01 Apr 2020 Acucela is now called Kubota Vision
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in USA (PO)